Myotonic Disorders clinical trials at UCSD

1 research study open to eligible people

Showing trials for

  • Global Study of Del-desiran for the Treatment of DM1

    open to eligible people ages 16-65

    A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

    San Diego, California and other locations

Last updated: